Retrospective Comparison of Capecitabine plus Oxaliplatin and Docetaxel plus S-1 as Adjuvant Chemotherapy for Pathological Stage III Gastric Cancer
Oncology · 21.05.2026 · 1-13
DOI: 10.1159/000552059 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Oncology, online erschienen am 21.05.2026. Verfasst von Toru Imai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Capecitabine, Docetaxel, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 24 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Adjuvant chemotherapy following surgical resection is the standard treatment for patients with pathological stage III (pStage III) gastric cancer (GC) in Japan. Capecitabine plus oxaliplatin (CapeOX) and docetaxel plus S-1 (DS) are recommended adjuvant regimens for this disease; however, no studies have compared the treatment outcomes of the two regimens. Therefore, this study aimed to evaluate the safety and efficacy of CapeOX versus DS as adjuvant chemotherapy in patients with pStage III GC.
Methods
We retrospectively reviewed the clinical information and treatment outcomes (including relapse-free survival [RFS] and adverse events) of patients with pStage III GC who received either CapeOX or DS as adjuvant chemotherapy at our institution from February 2016 to May 2022.
Results
A total of 73 patients (CapeOX, 31; DS 42) were included in this study. There was no significant difference in RFS between the two groups (3-year RFS: 37% in the CapeOX group vs. 44% in the DS group; hazard ratio [HR] = 1.30 [95% CI: 0.71–2.37], p = 0.400). In the multivariable analysis for RFS, treatment regimen was not identified as a prognostic factor for RFS (HR = 1.02, 95% CI: 0.49–2.09, p = 0.957). Compared with DS, CapeOX was associated with lower incidences of any-grade oral mucositis (10% vs. 50%, p < 0.001) and any-grade alopecia (6% vs. 74%, p < 0.001) and a higher incidence of any-grade peripheral sensory neuropathy (81% vs. 24%, p < 0.001).
Conclusion
This analysis suggests that CapeOX and DS offer comparable efficacy as adjuvant chemotherapy for pStage III GC in terms of RFS, while exhibiting distinct adverse event profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, hihirano@ncc.go.jp.
Zitieren
APA
Imai, T., Hirano, H., Shoji, H., Hirose, T., Okita, N., Takashima, A., & Kato, K. (2026). Retrospective Comparison of Capecitabine plus Oxaliplatin and Docetaxel plus S-1 as Adjuvant Chemotherapy for Pathological Stage III Gastric Cancer. Oncology, 1-13. https://doi.org/10.1159/000552059
Vancouver
Imai T, Hirano H, Shoji H, Hirose T, Okita N, Takashima A, et al. Retrospective Comparison of Capecitabine plus Oxaliplatin and Docetaxel plus S-1 as Adjuvant Chemotherapy for Pathological Stage III Gastric Cancer. Oncology. 2026:1-13. doi:10.1159/000552059
BibTeX
@article{Imai2026,
author = {Imai, Toru and Hirano, Hidekazu and Shoji, Hirokazu and Hirose, Toshiharu and Okita, Natsuko and Takashima, Atsuo and Kato, Ken},
title = {Retrospective Comparison of Capecitabine plus Oxaliplatin and Docetaxel plus S-1 as Adjuvant Chemotherapy for Pathological Stage III Gastric Cancer},
journal = {Oncology},
year = {2026},
pages = {1--13},
doi = {10.1159/000552059}
}
EUVIMED